DNA polymerase catalytic subunit · SINGLE PROTEIN · Herpes simplex virus (type 1 / strain 17)
This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.
Move to another high-traffic target or paste a specific ChEMBL target ID.
Structured disease, protein, and project context should read before the lower-level identity rail.
As of 2026-09-14DNA polymerase catalytic subunit shows approved-linked disease relevance led by Herpes simplex infection. 5 more disease programs remain visible in the same review block. 7 linked drugs keep the current disease frame grounded. Protein identity stays anchored to UniProt P04293. Start with Herpes simplex infection, then reuse UniProt P04293 as the stable protein anchor across project notes and exports.
Start with Herpes simplex infection, then reuse UniProt P04293 as the stable protein anchor across project notes and exports.
DNA polymerase catalytic subunit shows approved-linked disease relevance led by Herpes simplex infection. 5 more disease programs remain visible in the same review block. 7 linked drugs remain visible in the same block.
Start review with Herpes simplex infection because it currently carries approved-linked support. Linked drugs include ACYCLOVIR, ACYCLOVIR SODIUM, CIDOFOVIR, FAMCICLOVIR. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
Disease source · ChEMBL drug mechanism + indication proxyDNA polymerase catalytic subunit
Review this target as DNA polymerase catalytic subunit, mapped to UniProt P04293. Sequence length is 1235 aa.
Protein source · UniProt accession via ChEMBL component mappingKeep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.
This review treats DNA polymerase catalytic subunit as ChEMBL target CHEMBL1872, mapped to UniProt P04293. Disease framing currently uses the Open Targets-ready proxy contract.
Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.
Choose the first block or source based on the question you are trying to answer.
Start here when your first question is whether DNA polymerase catalytic subunit is the right protein anchor across sources, using UniProt P04293 as the stable mapping.
Jump to Protein ContextUse this block first when you need to confirm why Herpes simplex infection is currently framed as approved-linked support. It currently carries 7 linked drugs in the same disease frame.
Jump to Disease ContextOpen the one-page evidence card when you want the rationale, activity base, and attribution together.
Open Review-ready CardVerify identity, organism, and the fastest next research jumps from the same page.
| Preferred Name | DNA polymerase catalytic subunit |
| Target Type | SINGLE PROTEIN |
| Organism | Herpes simplex virus (type 1 / strain 17) |
| UniProt | P04293 |
Reviewable protein naming and mapping context for this target snapshot.
| Protein Label | DNA polymerase catalytic subunit |
| UniProt Accession | P04293 |
| Component Type | Protein |
| Sequence Length | 1235 aa |
DNA polymerase catalytic subunit
Review this target as DNA polymerase catalytic subunit, mapped to UniProt P04293. Sequence length is 1235 aa.
Open Targets-ready disease context using the current target-indication evidence contract.
DNA polymerase catalytic subunit shows approved-linked disease relevance led by Herpes simplex infection. 5 more disease programs remain visible in the same review block.
Start review with Herpes simplex infection because it currently carries approved-linked support. Linked drugs include ACYCLOVIR, ACYCLOVIR SODIUM, CIDOFOVIR, FAMCICLOVIR. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
| ChEMBL ID | pChEMBL | Type | Value (nM) | Phase |
|---|---|---|---|---|
| CHEMBL363625 | 6.52 | IC50 | 300.0 | Preclinical |
| CHEMBL195453 | 6.3 | IC50 | 500.0 | Preclinical |
| CHEMBL29711 | 6.3 | IC50 | 500.0 | Preclinical |
| CHEMBL194433 | 6.22 | IC50 | 600.0 | Preclinical |
| CHEMBL440033 | 5.92 | IC50 | 1200.0 | Preclinical |
| CHEMBL193952 | 5.48 | IC50 | 3300.0 | Preclinical |
| CHEMBL92173 | 4.41 | IC50 | 39000.0 | Preclinical |
| CHEMBL91679 | 4.36 | IC50 | 44000.0 | Preclinical |
| CHEMBL273301 | 4.28 | IC50 | 52000.0 | Preclinical |
| CHEMBL328911 | 4.27 | IC50 | 54000.0 | Preclinical |
| BAO Format | Assays | Compounds | Avg pChEMBL |
|---|---|---|---|
| single protein format | 4 | 19 | 4.9 |
| BAO Format | Assays | Compounds | Avg pChEMBL |
|---|---|---|---|
| cell-based format | 3 | 0 | — |
| assay format | 1 | 0 | — |